ZYDUS LIFESCIENCES | USFDA GRANTS ORPHAN DRUG DESIGNATION

Desidustat receives Orphan Drug Designation (ODD) from the USFDA for treating beta-thalassemia. • ODD supports medicines for rare diseases affecting <200,000 people in the US. • Desidustat, a novel oral HIF-PHI, aims to increase haemoglobin & red blood cell counts. • The designation offers development incentives such as tax credits & 7-year marketing exclusivity upon approval.